APA
Schreiber S., Kämpgen E., Wagner E., Pirkhammer D., Trcka J., Korschan H., Lindemann A., Dorffner R., Kittler H., Kasteliz F., Küpcü Z., Sinski A., Zatloukal K., Buschle M., Schmidt W., Birnstiel M., Kempe R. E., Voigt T., Weber H. A., Pehamberger H., Mertelsmann R., Bröcker E. B., Wolff K. & Stingl G. (19990622). Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study. : Human gene therapy.
Chicago
Schreiber S, Kämpgen E, Wagner E, Pirkhammer D, Trcka J, Korschan H, Lindemann A, Dorffner R, Kittler H, Kasteliz F, Küpcü Z, Sinski A, Zatloukal K, Buschle M, Schmidt W, Birnstiel M, Kempe R E, Voigt T, Weber H A, Pehamberger H, Mertelsmann R, Bröcker E B, Wolff K and Stingl G. 19990622. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study. : Human gene therapy.
Harvard
Schreiber S., Kämpgen E., Wagner E., Pirkhammer D., Trcka J., Korschan H., Lindemann A., Dorffner R., Kittler H., Kasteliz F., Küpcü Z., Sinski A., Zatloukal K., Buschle M., Schmidt W., Birnstiel M., Kempe R. E., Voigt T., Weber H. A., Pehamberger H., Mertelsmann R., Bröcker E. B., Wolff K. and Stingl G. (19990622). Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study. : Human gene therapy.
MLA
Schreiber S, Kämpgen E, Wagner E, Pirkhammer D, Trcka J, Korschan H, Lindemann A, Dorffner R, Kittler H, Kasteliz F, Küpcü Z, Sinski A, Zatloukal K, Buschle M, Schmidt W, Birnstiel M, Kempe R E, Voigt T, Weber H A, Pehamberger H, Mertelsmann R, Bröcker E B, Wolff K and Stingl G. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study. : Human gene therapy. 19990622.